Cardiology Topic

Acute coronary syndrome.

ECG in 10 min. hs-troponin 0/1-2 h. PCI on the clock. STEMI vs NSTE-ACS pathways, the high-sensitivity troponin algorithm, antiplatelet + anticoagulation choices, and reperfusion windows.

Reviewed June 2026 · verify against current guidelines

Diagnosis & Workup

Recognize. Confirm. Stage.

First 10 minutes

STEMI ECG criteria

Most leadsST elevation ≥1 mm in ≥2 contiguous leads (outside V2-V3).
V2-V3≥2 mm men ≥40 y · ≥2.5 mm men <40 y · ≥1.5 mm women.
Posterior MIST depression ≥0.5 mm in V1-V3 → obtain V7-V9. STE ≥0.5 mm in V7-V9 confirms.
LBBB or pacedNOT a STEMI equivalent in isolation. Requires clinical correlation.

NSTE-ACS ECG (any of; normal does NOT exclude)

ST depression≥0.5 mm in ≥2 contig leads, horizontal/downsloping · new or dynamic.
T-wave inversion>1 mm in ≥2 contig leads with dominant R.
Transient STESelf-resolving ST elevation.
STEMI = ECG criteria met above.
NSTE-ACS = symptoms without persistent STE; ↑ troponin (NSTEMI).
UA = symptoms + non-diagnostic ECG + normal troponin (historical category; now largely reclassified as NSTE-ACS in the hs-cTn era).
FMC first medical contacths-cTn high-sensitivity cardiac troponinSTE ST elevationLBBB left bundle branch blockNSTE-ACS non-ST-elevation ACSNSTEMI non-ST-elevation MIUA unstable angina
ECG Pearls

OMI patterns to know.

Standard ED teaching, not in the 2025 ACS guideline. Useful when ECG looks "not quite STEMI" but artery is occluded.

Patterns

Posterior MISTD ≥0.5 mm in V1-V3 + tall R waves → V7-V9 (STE ≥0.5 mm confirms).
deWinter TUpsloping STD at J point + tall symmetric T waves V1-V6 → proximal LAD.
WellensBiphasic (Type A) or deeply inverted (Type B) T in V2-V3 during pain-free interval → critical LAD; AVOID stress.
aVR + diffuse STDSTE aVR + diffuse STD → LMCA, proximal LAD, or 3-vessel disease.

Sgarbossa criteria (LBBB or paced rhythm)

Concordant STE≥1 mm in any lead with positive QRS (highly specific).
Concordant STD≥1 mm in V1, V2, or V3 (highly specific).
Discordant STEOriginal: ≥5 mm with negative QRS.
Modified (Smith): ST/S ratio ≥ 0.25 (more sensitive).
Recognize OMI even when STEMI criteria are not met. Activate cath, get a second read, get an echo.
OMI occlusion myocardial infarctionLAD left anterior descendingLMCA left main coronary arterySTE ST elevationSTD ST depressionLBBB left bundle branch block
Acute Management

Antiplatelet + anticoagulation.

DAPT

Aspirin162-325 mg chewed nonenteric load → 75-100 mg daily.
Ticagrelor180 mg load → 90 mg BID. Preferred P2Y12.
Prasugrel60 mg load → 10 mg daily. 5 mg if <60 kg or ≥75 y. PCI only.
Clopidogrel300-600 mg load → 75 mg daily. Fibrinolysis: 300 mg if ≤75 y;
no load if >75 y.

Anticoagulation

UFH60 U/kg bolus (max 4000 U) → 12 U/kg/h (max 1000 U/h). aPTT goal 60-80 sec.
Enoxaparin1 mg/kg SC q12h → q24h if CrCl <30.

β-blocker

Within 24 hOral β-blocker (metoprolol, carvedilol, or bisoprolol) unless: acute HF/low output · shock risk · severe bradycardia · PR >0.24 s · 2°/3° AV block · severe asthma.
Metoprolol: tartrate acutely → succinate long-term.
Prasugrel is contraindicated in prior stroke or TIA.
In NSTE-ACS without an invasive plan, ticagrelor is preferred over prasugrel.
If CABG is possible, defer the P2Y12 load until coronary anatomy is known (pre-op washout: ticagrelor 3-5 d · clopidogrel 5 d · prasugrel 7 d).
DAPT dual antiplatelet therapyP2Y12 platelet ADP-receptor inhibitorUFH unfractionated heparinaPTT activated partial thromboplastin timeCrCl creatinine clearanceHF heart failureTIA transient ischemic attackCABG coronary artery bypass graftNSTE-ACS non-ST-elevation ACS
Reperfusion

On the clock.

STEMI timing

PCI directFMC-to-device ≤90 min.
PCI transferFMC-to-device ≤120 min.
FibrinolysisAnticipated PCI delay >120 min · no contraindications · sx <12 h.
Post-lysisTransfer ALL for angio 2-24 h, even if successful.

NSTE-ACS invasive timing

Immediate <2 hVery high-risk: refractory angina · hemodynamic/electrical instability · shock · acute HF.
Early <24 hHigh-risk: GRACE >140 · dynamic ST · rising troponin.
<72 h before d/cIntermediate-risk: GRACE 109-140 · stable troponin · no ongoing ischemia.
Routine or selectiveLower-risk: GRACE <109 · TIMI <2.

Procedural standards

AccessRadial > femoral.
ImagingIVUS or OCT for complex PCI.
Complete revascStable STEMI + MVD → revasc non-IRA.
Shock → culprit-only.
FMC first medical contactGRACE Global Registry of Acute Coronary EventsTIMI Thrombolysis In Myocardial InfarctionHF heart failured/c dischargeMVD multi-vessel diseaseIRA infarct-related arteryIVUS intravascular ultrasoundOCT optical coherence tomography
Pitfalls

What gets missed.

Common errors

Transfusion (MINT)

ThresholdHb ~10 g/dL reasonable in ACS + acute/chronic anemia, no active bleeding.
Normal troponin and a non-diagnostic ECG do NOT rule out NSTE-ACS. Repeat the ECG. Repeat the troponin. Risk-stratify.
CrCl creatinine clearanceLBBB left bundle branch blockTIA transient ischemic attackP2Y12 platelet ADP-receptor inhibitorCABG coronary artery bypass graftHb hemoglobinMINT Myocardial Ischemia and Transfusion trialNSTE-ACS non-ST-elevation ACS
Long-term

DAPT strategy + discharge.

DAPT duration & de-escalation

DefaultDAPT ≥12 mo if not HBR.
Ticagrelor monoDAPT → ticagrelor alone ≥1 mo post-PCI is reasonable to ↓ bleeding.
De-escalateTicagrelor or prasugrel → clopidogrel after 1 mo may be reasonable to ↓ bleeding.
HBRSingle antiplatelet after 1 mo may be considered.
OAC + PCIDrop aspirin at 1-4 wk; continue P2Y12 (clopidogrel preferred) + OAC.

Secondary prevention

StatinHigh-intensity. Add ezetimibe if LDL-C ≥70 on max statin.
ACEi / ARBIndicated if LVEF ≤40%, HTN, DM, or anterior STEMI. Reasonable in other ACS.
MRAIf LVEF ≤40% with HF or DM, on ACEi/ARB + β-blocker.
Cardiac rehabRefer all. Home-based acceptable.
Ticagrelor monotherapy at 1 mo = practice-changing 2025 update. Reasonable to ↓ bleeding in patients tolerating ticagrelor.
DAPT dual antiplatelet therapyP2Y12 platelet ADP-receptor inhibitorHBR high bleeding riskOAC oral anticoagulantLDL-C low-density lipoprotein cholesterolACEi angiotensin-converting enzyme inhibitorARB angiotensin receptor blockerMRA mineralocorticoid receptor antagonistLVEF left ventricular ejection fractionHF heart failure

Sources

Verify against current guidelines and local protocol before acting.

  1. Rao SV et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation 2025;151:e771-e862 (copublished JACC 2025;85:2135-2237).
  2. Thiele H et al. CULPRIT-SHOCK: culprit-only vs multivessel PCI in cardiogenic shock. NEJM 2017.
  3. Carson JL et al. MINT: restrictive vs liberal transfusion in MI + anemia. NEJM 2023.
  4. Mehran R et al. TWILIGHT: ticagrelor monotherapy after PCI. NEJM 2019.

Downloads

Every card for this topic — carousels and tables, print-ready for the wards or for sharing.

Acute coronary syndrome.
Carousel8 slides
ACS — high-yield reference.
High-yield tableACS — high-yield reference.